Selected Citation:
Costain, W. J. et al. Pharmacological characterization of emerging synthetic cannabinoids in HEK293T cells and hippocampal neurons. Eur. J. Pharmacol. 786, 234–245 (2016).

About Human Cannabinoid Receptor 1 (CB1/CNR1) Stable Cell Line

Cannabinoid Receptor 1 (CB1), encoded by the CNR1 gene, is a Class A G protein-coupled receptor (GPCR) and the most abundant GPCR in the mammalian central nervous system. CB1 is the primary receptor for endogenous cannabinoids (endocannabinoids), including anandamide (AEA) and 2-arachidonoylglycerol (2-AG), as well as exogenous cannabinoids derived from Cannabis sativa, including Δ9-tetrahydrocannabinol (THC). Upon activation, CB1 primarily couples to Gi/o proteins, resulting in inhibition of adenylate cyclase activity, reduction of intracellular cAMP levels, modulation of calcium and potassium channels, and regulation of multiple downstream signaling pathways involved in neurotransmission and cellular homeostasis.

CB1 is highly expressed throughout the brain, including the cortex, hippocampus, basal ganglia, cerebellum, and limbic system, as well as in peripheral tissues such as adipose tissue, liver, gastrointestinal tract, and reproductive organs. The endocannabinoid-CB1 signaling system plays critical roles in appetite regulation, energy balance, pain perception, mood, memory, reward processing, motor control, neuroprotection, and immune modulation. Dysregulation of CB1 signaling has been implicated in obesity, addiction, chronic pain, anxiety disorders, depression, neurodegenerative diseases, and metabolic disorders, making CB1 one of the most extensively studied GPCR targets in neuroscience and drug discovery.

eEnzyme's Human CB1 Stable Cell Line provides a reliable and reproducible cellular platform for investigating CB1-mediated signaling pathways and evaluating cannabinoid receptor-targeted therapeutics. The cell line enables quantitative assessment of agonists, antagonists, inverse agonists, allosteric modulators, phytocannabinoids, and synthetic cannabinoids through cAMP assays, reporter gene assays, β-arrestin recruitment studies, and other GPCR functional screening platforms. Researchers can utilize this stable cell line for receptor characterization, compound profiling, potency determination, lead optimization, and high-throughput screening applications supporting neuroscience, pain, and metabolic disease research.

Applications of the CB1 Stable Cell Line

• CB1 receptor pharmacology studies
• Endocannabinoid signaling investigations
• Agonist and antagonist screening
• Cannabinoid drug discovery and development
• Pain and analgesia research
• Obesity and metabolic disease studies
• cAMP and GPCR functional assays
• High-throughput screening applications

Biological Significance of CB1

CB1 is a central regulator of the endocannabinoid system and plays essential roles in maintaining neuronal and physiological homeostasis. Activation of CB1 modulates neurotransmitter release throughout the central nervous system, influencing learning, memory, appetite, pain sensation, emotional responses, and reward pathways. The receptor mediates many of the pharmacological effects of cannabinoids and has become an important target for therapies aimed at treating chronic pain, neurological disorders, addiction, obesity, and metabolic diseases. In addition to its neurological functions, CB1 signaling regulates lipid metabolism, glucose homeostasis, gastrointestinal function, and inflammatory responses. Because of its broad physiological significance and therapeutic potential, CB1 remains one of the most important GPCR targets in neuroscience, cannabinoid biology, and translational drug discovery. The CB1 Stable Cell Line provides a valuable tool for studying cannabinoid receptor pharmacology and advancing the development of next-generation CB1-targeted therapeutics.